GlassScriptPhysician profile
Mitchell Todd Alderson
NPI 1942204912
$3,347.77
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $832 · 2021: $906 · 2022: $169 · 2023: $389 · 2024: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $414.38 | 2021-2024 | Azure Xt Dr Mri Surescan |
| Amgen INC. | $342.43 | 2019-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $293.80 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $284.74 | 2019-2021 | |
| Pfizer INC. | $261.47 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $232.01 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $229.70 | 2019-2023 | Xarelto |
| Cvrx, INC. | $157.46 | 2023 | Barostim Neo System |
| Medtronic Vascular, INC. | $144.93 | 2020 | |
| Biotronik INC. | $135.67 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $127.04 | 2020-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $121.23 | 2019-2021 | |
| Amarin Pharma, INC. | $97.21 | 2019-2021 | |
| Fujifilm Healthcare Americas Corporation | $94.65 | 2021 | |
| Abbott Laboratories | $83.12 | 2021-2023 | Diamondback Peripheral |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $54.37 | 2021-2022 | |
| Edwards Lifesciences Corporation | $50.20 | 2019-2021 | |
| Astellas Pharma US INC | $47.98 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.52 | 2019-2021 | |
| Boston Scientific Corporation | $30.85 | 2024 | Opticross |
| Regeneron Healthcare Solutions, INC. | $26.62 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.33 | 2023 | Onpattro |
| Esperion Therapeutics, INC. | $21.78 | 2020 | |
| Bardy Diagnostics, INC. | $14.00 | 2019 | |
| Chiesi USA, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Alderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.